This story has been updated from a previous version.

NEW YORK, Nov 7 -  Incyte and Oxford GlycoSciences said Tuesday they would end the exclusive profit-sharing proteomics deal they began in January 1998 and that future collaboration will occur on a non-exclusive contract basis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.